Johnson & Johnson announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman of Innovative Medicine and member of the Executive Committee effective September 1, 2026. Tom Cavanaugh, currently Group Chairman for North America in Innovative Medicine, has been appointed to succeed her and will join the Executive Committee on the same date. Under Taubert's leadership, the Innovative Medicine business grew to more than $60 billion in annual revenue. Johnson & Johnson operates as a global healthcare company with segments in innovative medicine and medtech.

Johnson & Johnson completed the acquisition of Firefly Bio for $1 billion in cash and entered into a strategic collaboration with Sail Biomedicines, including an equity investment and an exclusive option to acquire Sail for $2.58 billion. These transactions are expected to dilute adjusted operational EPS and adjusted EPS by approximately $0.64 in 2026 ($0.46 from Firefly, $0.18 from Sail) and $1.36 in 2027. Consequently, the company updated its full-year 2026 guidance, lowering the midpoint for adjusted operational EPS to $10.94 (from $11.58), adjusted sales growth to a 6.2%-6.8% range, and estimated reported sales to a $100.8B-$101.4B range. Johnson & Johnson is a diversified healthcare company engaged in the research, development, manufacture, and sale of products in the pharmaceutical, medical devices, and consumer health sectors.

Johnson & Johnson announced a comprehensive resolution agreement for its remaining ovarian talc litigation, conditioned on at least 95% participation by claimants. The company committed $5.5 billion to settle these claims through per-claim payments, with the first tranche capped at $3 billion in 2027 and no further payments due before 2028. This settlement follows a favorable Multi-District Litigation court ruling on specific causation that undermined the plaintiffs' scientific evidence. Johnson & Johnson operates as a global healthcare company developing innovative medicines, medical devices, and consumer health products.

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion, a 6.6% increase over the prior year, with adjusted EPS of $2.90. The company raised its full-year 2026 guidance, increasing estimated reported sales to a midpoint of $101.1 billion and adjusted EPS guidance by $0.13 to a midpoint of $11.68. Key growth drivers included the Innovative Medicine segment, specifically oncology products like Darzalex and Carvykti. The company also announced a new supply chain restructuring program in the Innovative Medicine segment with estimated costs between $650 million and $750 million to be completed by 2029. The company operates in the healthcare industry, specializing in innovative medicine and medical technology.

Johnson & Johnson shareholders elected all 12 director nominees and approved executive compensation and the appointment of PricewaterhouseCoopers LLP as auditor at the company's 2026 Annual Meeting. A shareholder proposal to mandate an independent board chair was defeated, receiving 406,353,048 votes in favor and 1,326,857,173 votes against.